Ikena Oncology Statistics
Total Valuation
Ikena Oncology has a market cap or net worth of $55.01 million. The enterprise value is -$52.43 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 7.88% in one year.
| Current Share Class | 41.89M |
| Shares Outstanding | 48.26M |
| Shares Change (YoY) | +7.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 19.00% |
| Float | 7.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.31, with a Debt / Equity ratio of 0.06.
| Current Ratio | 13.31 |
| Quick Ratio | 12.97 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.49% and return on invested capital (ROIC) is -20.81%.
| Return on Equity (ROE) | -30.49% |
| Return on Assets (ROA) | -19.87% |
| Return on Invested Capital (ROIC) | -20.81% |
| Return on Capital Employed (ROCE) | -39.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.17M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Ikena Oncology has paid $153,000 in taxes.
| Income Tax | 153,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.63% in the last 52 weeks. The beta is 0.48, so Ikena Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -11.63% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 44.70 |
| Average Volume (20 Days) | 97,538 |
Short Selling Information
The latest short interest is 128,854, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 128,854 |
| Short Previous Month | 132,743 |
| Short % of Shares Out | 0.27% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | -30.88M |
| Operating Income | -48.27M |
| Pretax Income | -66.78M |
| Net Income | -41.71M |
| EBITDA | -47.91M |
| EBIT | -48.27M |
| Earnings Per Share (EPS) | -$0.87 |
Full Income StatementBalance Sheet
The company has $114.05 million in cash and $6.61 million in debt, giving a net cash position of $107.44 million or $2.23 per share.
| Cash & Cash Equivalents | 114.05M |
| Total Debt | 6.61M |
| Net Cash | 107.44M |
| Net Cash Per Share | $2.23 |
| Equity (Book Value) | 118.25M |
| Book Value Per Share | 2.45 |
| Working Capital | 108.21M |
Full Balance SheetCash Flow
| Operating Cash Flow | -38.26M |
| Capital Expenditures | n/a |
| Free Cash Flow | -38.26M |
| FCF Per Share | -$0.79 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |